Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINT: Hydroxyurea for Secondary Stroke Prevention in Sickle Cell Anemia
NCT02675790Phase 3Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jan 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydroxyurea in sickle cell anemia (SCA) (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Recurrence of clinically overt stroke, transient ischemic attack or death at 36 months. Started Jan 2017; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT02675790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675790.